Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma
Autore:
Wilson, MW; Rodriguez-Galindo, C; Haik, BG; Moshfeghi, DM; Merchant, TE; Pratt, CB;
Indirizzi:
St Jude Childrens Hosp, Dept Surg, Memphis, TN 38105 USA St Jude ChildrensHosp Memphis TN USA 38105 t Surg, Memphis, TN 38105 USA St Jude Childrens Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA St Jude Childrens Hosp Memphis TN USA 38105 Oncol, Memphis, TN 38105 USA St Jude Childrens Hosp, Dept Radiat Oncol, Memphis, TN 38105 USA St Jude Childrens Hosp Memphis TN USA 38105 Oncol, Memphis, TN 38105 USA Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA Univ Tennessee Memphis TN USA 38163 i, Dept Pediat, Memphis, TN 38163 USA
Titolo Testata:
OPHTHALMOLOGY
fascicolo: 11, volume: 108, anno: 2001,
pagine: 2106 - 2114
SICI:
0161-6420(200111)108:11<2106:MCANTF>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOCAL TREATMENT; BRAIN-TUMORS; CHILDREN; CHEMOREDUCTION; CARBOPLATIN; RADIOTHERAPY; MANAGEMENT; RADIATION; RECURRENT; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Wilson, MW 956 Court Ave,Suite D228, Memphis, TN 38163 USA 956 Court Ave,Suite D228 Memphis TN USA 38163 is, TN 38163 USA
Citazione:
M.W. Wilson et al., "Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma", OPHTHALMOL, 108(11), 2001, pp. 2106-2114

Abstract

Purpose. To evaluate the efficacy of multiagent chemotherapy in the neoadjuvant treatment of retinoblastoma. Design: Noncomparative, prospective, case series. Participants. Twenty consecutive patients with multifocal intraocular retinoblastoma (4 unilateral, 16 bilateral [36 eyes]). Intervention: Eight cycles of chemotherapy with carboplatin and vincristine were administered at 3-week intervals over a 6-month period. Supplementaltherapy was withheld until disease progression was documented. Main Outcome Measures:. Disease progression (defined as tumor growth, vitreous or subretinal seed progression, and new tumor formation), delay of external beam radiotherapy, and ocular survival. Results: Thirty-six eyes were treated. Eighteen eyes had Reese-Ellsworth group I-III tumors, and 16 eyes had Reese-Ellsworth group IV-V tumors, at diagnosis. Two patients, who had unilateral disease at diagnosis, subsequently had tumors develop in the contralateral eye. Nineteen of 20 patients (95%) completed eight cycles of chemotherapy without disease progression. Threeeyes of three different patients were successfully treated with chemotherapy alone. Thirty-three of 36 eyes (92%) progressed after completion of chemotherapy: 15 of the 18 eyes (83.3%) with Reese-Ellsworth group I-III and 16of 16 eyes (100%) with Reese-Ellsworth group IV-V tumors. Seventeen eyes (52%) had growth of a tumor, whereas 14 eyes (42%) had progressive vitreous seeding, and 2 eyes (6%) had new tumors develop. Fifteen eyes (42%) required external beam radiotherapy. Twenty-nine of 36 (80.5%) eyes were salvaged. The median follow-up after chemotherapy was 19 months (range, 3-42 months). Conclusions. Multiagent chemotherapy alone does not ensure a cure for multifocal intraocular retinoblastoma. Supplemental focal therapy is needed to control disease progression. Ophthalmology 2001;108: 2106-2115 (C) 2001 by the American Academy of Ophthalmology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 01:39:09